HLS Enterprise Value Multiple from 2010 to 2026

HLS Stock  CAD 4.50  0.01  0.22%   
HLS Therapeutics Enterprise Value Multiple yearly trend continues to be very stable with very little volatility. Enterprise Value Multiple is likely to drop to 5.34. During the period from 2010 to 2026, HLS Therapeutics Enterprise Value Multiple quarterly data regression pattern had range of 30.0032 and standard deviation of  8.90. View All Fundamentals
 
Enterprise Value Multiple  
First Reported
2010-12-31
Previous Quarter
7.04
Current Value
5.34
Quarterly Volatility
8.90218963
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Check HLS Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among HLS Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 13.2 M, Interest Expense of 12.2 M or Total Revenue of 55.7 M, as well as many indicators such as Price To Sales Ratio of 1.19, Dividend Yield of 0.0102 or PTB Ratio of 0.73. HLS financial statements analysis is a perfect complement when working with HLS Therapeutics Valuation or Volatility modules.
  
This module can also supplement various HLS Therapeutics Technical models . Check out the analysis of HLS Therapeutics Correlation against competitors.
Evaluating HLS Therapeutics's Enterprise Value Multiple across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into HLS Therapeutics's fundamental strength.

Latest HLS Therapeutics' Enterprise Value Multiple Growth Pattern

Below is the plot of the Enterprise Value Multiple of HLS Therapeutics over the last few years. It is HLS Therapeutics' Enterprise Value Multiple historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in HLS Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Enterprise Value Multiple10 Years Trend
Slightly volatile
   Enterprise Value Multiple   
       Timeline  

HLS Enterprise Value Multiple Regression Statistics

Arithmetic Mean9.74
Coefficient Of Variation91.41
Mean Deviation7.48
Median7.04
Standard Deviation8.90
Sample Variance79.25
Range30.0032
R-Value0.41
Mean Square Error70.59
R-Squared0.16
Significance0.11
Slope0.72
Total Sum of Squares1,268

HLS Enterprise Value Multiple History

2026 5.34
2025 7.04
2024 7.82
2023 14.71
2022 18.04
2021 17.78
2020 21.52

About HLS Therapeutics Financial Statements

HLS Therapeutics investors utilize fundamental indicators, such as Enterprise Value Multiple, to predict how HLS Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Enterprise Value Multiple 7.04  5.34 

Other Information on Investing in HLS Stock

HLS Therapeutics financial ratios help investors to determine whether HLS Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in HLS with respect to the benefits of owning HLS Therapeutics security.